Eftansomatropin alfa
- Generic Name
- Eftansomatropin alfa
- Drug Type
- Biotech
- CAS Number
- 1905448-17-0
- Unique Ingredient Identifier
- 1CPV8ZQB38
- Background
Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment. It is under investigation for the treatment of growth hormone deficiency.
Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03309891
- Locations
- 🇺🇦
Odessa National Medical University, Odessa Regional Children's Hospital, Odessa, Ukraine
A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02946606
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath